The Week In Biopharma, June 6 – 10
Contract Development and Manufacturing (CDMO)
- Corvia nets $54M to continue development of its shunt implant for heart failure (USA)
- Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy (France/USA)
- Exothera develops exoREADY, a ready-to-use viral vector production platform, to accelerate advanced therapy manufacture at scale (Belgium)
- Curia and Replicate Bioscience Enter srRNA Collaboration (USA)
- CPC’s AseptiQuik Genderless Connector Makes Sterile Connections and Disconnections Using One Product (USA)
- Manny Villafaña’s Medical 21 Unveils Groundbreaking MAVERICS Graft System (USA)
- Jubilant Snags $146.6M US Contract to Double Injectables Production (USA)
- Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform (USA)
- Thermo Fischer Scientific Partners with TransMIT GmbH (USA/Germany)
Biopharma
- Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers (USA)
- Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement (Canada/USA)
- European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (Switzerland)
- Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform (China)
- Pfizer Opens €300M State-of-the-Art Facility in Freiburg, (Germany)
- Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer (China)
- RAD adds brain tumor technology to portfolio (Australia)
- REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility (USA)
- Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform (China)
- Astellas opens new $100M gene therapy production plant (Japan)
- Betting on both types of CAR-T, Tessa grabs $126M series A to push assets through clinic (Singapore)
- SMC Launches Cambridge Pharma (UK)
- Catalent and MigVax to Develop Oral COVID Vaccine (USA/Israel)
- Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting (USA)
- Accord Healthcare Releases Generic Drug Proven Effective in Treating Major Depressive Disorder in Adults (Ireland)
- Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension (USA)
- OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate (USA/China)
- Roswell Biotechnologies Forges Early Research Collaboration for Innovative Drug Discovery with UCB (USA/Belgium)
- Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers (Germany)
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer (Germany/USA)
- Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases (USA)
- European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma (Switzerland)
- FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (USA)
- PineTree Therapeutics, Inc. Secures $23.5 Millionv of Series A1 Funding to Develop Cutting Edge Platform Technology to Create Therapeutic Assets for Unmet Medical Needs (USA)
- SATT[1] Conectus and Find Therapeutics Sign Licensing Agreement to Develop a Promising New Therapy for Multiple Sclerosis and other demyelinating diseases (Canada/France)
- Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy (USA)
- Rockwell Medical Closes $15 Million Financing from Leading Healthcare Investor (USA)
- Cancer vaccine biotech CimCure raises € 5 million in seed round investment led by Positron Ventures (Netherlands)
- Sanofi moves into big Cambridge HQ, where 2,500 will work (UK)
- Racing Sanofi, ImmunOs bags $74M for myeloid checkpoint trials in cancer patients (Switzerland)
- Code Bio launches with $75M to reinvent genetic medicine for rare and not-so-rare diseases (USA)
- WuXi Biologics Launches Commercial Drug Product Facility for Pre-Filled Syringes (China)
- Sana Biotechnology to Develop Manufacturing Facility in Bothell (USA)
- FDA Approves Riabni™ (Rituximab-Arrx), A Biosimilar to Rituxan® (Rituximab), For Adults With Moderate To Severe Rheumatoid Arthritis (USA)
- Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines (USA)
- Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update (Australia)
- With Vascepa sales tanking, Amarin cuts US headcount by 65%, replaces CFO (USA)
- GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older (USA)
- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease (USA/Canada)
Artificial Intelligence
- Vironix Health has Partnered with The Landon Pediatric Foundation to Bring AI-Healthcare Technology to Southern California (USA)
- Scopio Labs Awarded FDA Clearance for High Throughput Hematology Digital Cell Morphology Platform, Replacing Microscopes with Digitization (Israel)
- SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS (Switzerland)
- Bristol Myers pays $80M to AI firm Owkin as part of cardiovascular trial accord (USA)
- Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory (USA)
